Overview of Nisaid

This section defines the medication Nisaid (Oxaprozin), detailing its core classification, composition, and general purpose as a pharmaceutical entity.

Property	Description
Active ingredient	Oxaprozin (INN)
Form	Tablet (Oral administration)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose	Anti-inflammatory, analgesic, and antipyretic relief
Origin	Synthetic compound (Propionic acid derivative)

Defining Nisaid: Classification and Active Ingredient

Nisaid is the trade name for a prescription-only medication whose single active ingredient is the chemical compound Oxaprozin. This substance is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), placing it within the major pharmacological category used to modulate systemic inflammatory processes. The medication is clinically recognized for its systemic delivery, providing relief throughout the body rather than just at a topical site.

Pharmaceutical Form and Chemical Nature

The medication is supplied as a tablet intended for oral administration, often formulated for an extended-release effect, which is a key distinguishing characteristic. Chemically, Oxaprozin is identified as a propionic acid derivative, a specific subclass of NSAIDs. Its unique structure results in a long plasma half-life, which facilitates sustained anti-inflammatory and analgesic effects. The extended duration of action is a primary differentiator of Nisaid within its class.

Core Therapeutic Purpose of Oxaprozin

The generalized therapeutic purpose of Oxaprozin is derived directly from its function as an NSAID. The drug’s mechanism involves inhibiting the synthesis of prostaglandins, chemical messengers that promote pain and swelling. By modulating these agents, the drug delivers a triple-action benefit: it provides analgesic relief from discomfort, exerts an anti-inflammatory effect to mitigate swelling, and possesses antipyretic properties to reduce fever. This capability makes it suitable for managing persistent inflammatory discomfort.

Regulatory References

FDA label for Oxaprozin

What side effects are possible with Nisaid?

The safety profile of Nisaid (Oxaprozin) is defined by officially documented adverse reactions classified by frequency and involvement of specific body systems, consistent with its classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Adverse Reaction Scope

Key adverse reaction categories: The overall profile is characterized by effects primarily involving Gastrointestinal Disorders, Cardiovascular Thrombotic Events, and potential effects on Renal and Hepatobiliary systems.

Frequency classification: Reactions documented as Common in regulatory labeling include Gastrointestinal effects like Dyspepsia, Diarrhea, Nausea, and Abdominal pain, as well as general effects such as Headache and Rash. Rare but documented reactions include severe dermatological events like Stevens-Johnson Syndrome (SJS) and severe liver injury.

System-organ classes involved: Adverse effects are formally grouped in regulatory documents and include Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, Vascular Disorders (e.g., Hypertension), and Renal and Urinary Disorders.

Serious adverse reactions (as documented in regulatory sources): Regulatory information highlights the risk of serious Gastrointestinal ulceration, bleeding, and perforation, which can occur without warning symptoms at any time during use. An increased risk of serious Cardiovascular Thrombotic Events, including Myocardial Infarction and Stroke, is also documented.

Population- and Exposure-Specific Safety

Population-specific safety considerations: Older Adults are at a greater documented risk for serious gastrointestinal adverse events. Use is Contraindicated in the third trimester of pregnancy due to the risk of premature closure of the fetal Ductus Arteriosus. Safety statements exist for use in treating Juvenile Rheumatoid Arthritis (JIA) in pediatric patients aged 6 years and older.

Dose- or exposure-related patterns: The increased risk of serious cardiovascular thrombotic events may occur early in treatment and appears to increase with the duration of use.

Safety-related restrictions or limitations: Nisaid is Contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and in individuals with a known hypersensitivity to Oxaprozin, aspirin, or other NSAIDs.

Connection to the overall safety profile

These official safety domains structure the understanding of risks by categorizing adverse events into common, expected occurrences and critically serious, low-incidence risks. The regulatory profile emphasizes the potential for major organ system involvement (GI, Cardiac, Renal) and defines clear limitations based on patient context and treatment duration.

Overdose and Emergency Response

Nisaid (Oxaprozin) overdosage requires immediate medical attention due to the potential for severe systemic toxicity. Symptoms following an acute overdose of this Non-Steroidal Anti-Inflammatory Drug (NSAID) are often initially limited to central nervous system effects such as lethargy, drowsiness, dizziness, confusion, and sometimes severe headache or tinnitus. Gastrointestinal effects like nausea, vomiting, and epigastric pain are also common overdose presentations.

However, serious, life-threatening outcomes can occur, including acute renal failure, respiratory depression, and severe cardiovascular thrombotic events like myocardial infarction (MI) and stroke. The risk of gastrointestinal bleeding, ulceration, or perforation—which can be fatal—is a critical concern in any overdose scenario. Elderly patients are noted to be at greater risk for these serious gastrointestinal events, which require careful monitoring.

Management is symptomatic and supportive, as there is no specific antidote. Immediate emergency medical help must be sought right away for any signs of a heart attack or stroke (such as chest pain, slurred speech, or weakness in one side of the body), or if the patient experiences seizures, coma, or difficulty breathing. Gastric decontamination, such as administering activated charcoal, may be considered by medical professionals if the ingestion occurred within four hours and involved a large overdosage (defined as 5 to 10 times the usual dose). Contacting the Poison Control Center is also advisable for expert guidance.

Therapeutic Uses of Nisaid

What Nisaid Treats: Main Uses and Benefits

Nisaid (Oxaprozin) is indicated for the relief of the signs and symptoms of specific chronic conditions, primarily Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JIA) in pediatric patients aged 6 years and older.

Symptom Relief in Chronic Joint Conditions

Nisaid is commonly used across conditions characterized by periods of heightened symptoms related to chronic inflammatory joint diseases. The medication is considered relevant for easing symptoms that interfere with daily functioning, specifically addressing chronic joint pain, accompanying swelling, and physical stiffness. This assistance may support patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

“It is commonly used to provide supportive relief in diseases like rheumatoid and osteoarthritis, which are marked by inflammatory or irritative states and symptoms related to physical discomfort.”

Its formulation may be part of symptomatic management for continuing relief, which assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Quick Facts & Indications Summary

Quick Fact: Symptomatic Relief in Conditions Presenting with Systemic or Localized Discomfort

The primary indications for Nisaid are relevant for easing symptoms associated with Osteoarthritis, Rheumatoid Arthritis, and Juvenile Rheumatoid Arthritis. It is applied across domains where additional symptomatic support is needed for persistent conditions.

Regulatory References

National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Nisaid, an analgesic and anti-inflammatory drug belonging to the nonsteroidal anti-inflammatory drug (NSAID) class, is generally suitable for the relief of pain and inflammation. However, its use is associated with known risks, and it is contraindicated in several patient populations.

Contraindicated Use

Nisaid should not be used by patients with:

A known allergy or hypersensitivity to any NSAID, including a history of asthma, hives, or other allergic reactions triggered by aspirin or other NSAIDs.
Active gastrointestinal issues, such as a peptic ulcer or gastrointestinal bleeding.
Severe kidney failure or liver failure.
Severe heart failure or shortly after coronary artery bypass graft (CABG) surgery.
Pregnancy, particularly during the third trimester, due to potential harm to the developing fetus.

Use with Caution

Certain individuals are at an increased risk of adverse effects and should only use Nisaid under the direct supervision of a healthcare professional. These high-risk groups include:

Older adults (typically aged 65 and above).
Patients with a history of heart disease, uncontrolled hypertension, or heart failure.
Individuals with a history of gastrointestinal issues, such as Crohn's disease or ulcerative colitis.
Patients taking certain other medications, such as anticoagulants (blood thinners) or diuretics.

What should I know about interactions with other medicines?

The official regulatory profile for Nisaid (Oxaprozin) details clinically significant interactions related to pharmacodynamic co-effects and alterations in drug clearance. The medication is contraindicated for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, and in patients with a history of aspirin-sensitive asthma or hypersensitivity reactions to other non-steroidal anti-inflammatory drugs.

Co-administration may affect the plasma exposure of other medicines. Nisaid has been documented to cause elevations in plasma levels of both Lithium and Methotrexate due to a reduction in their renal clearance. Similarly, the serum concentration and half-life of Digoxin may be increased.

In terms of pharmacodynamic effects, the use of Oxaprozin with anticoagulants (e.g., Warfarin) or medicines that interfere with hemostasis (e.g., SSRIs) carries an increased risk of serious bleeding. The drug can also diminish the therapeutic effect of antihypertensives (ACE Inhibitors, ARBs) and diuretics. This reduction of effect, coupled with the risk of acute renal failure, is specifically noted as heightened in elderly, volume-depleted, or renally impaired patients taking ACE Inhibitors or ARBs.

A precise timing rule exists for Pemetrexed, requiring dosing to be interrupted for five days before, the day of, and two days following its administration. Furthermore, concomitant use with alcohol increases the risk of gastrointestinal mucosal bleeding.

Mechanism of Action

Modulation of Eicosanoid Pathways via Enzyme Inhibition

This domain covers the primary biological action of Oxaprozin: the reversible, non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking the enzymatic conversion of arachidonic acid, the mechanism severely limits the synthesis of prostaglandins and other eicosanoids throughout the body . This action thereby initiates a cascade that reduces the chemical signaling associated with the activation of inflammatory, nociceptive, and central thermoregulatory pathways.

️ Complementary Control of Inflammatory Cell Signaling

This secondary domain describes the drug's COX-independent actions, which involve the modulation of crucial intracellular pathways, such as the NF-kappa B (NF-kappaB) and Akt/IKK signaling cascades in immune cells. This mechanism modulates the survival and activation of pro-inflammatory cells, regulating the cellular processes that govern chronic inflammatory states. This complementary activity modulates the biological processes that perpetuate cellular inflammatory activity.

Dosage and Administration Information

How to Use Nisaid (Oxaprozin): Instructions

This section details the administration and dosing guidelines for Nisaid (Oxaprozin), focusing on how the medicine is used in clinical practice.

Administration and Dosage Forms

Nisaid is for oral administration as a tablet (or caplet/capsule) and is supplied in strengths such as 600 mg. The medication is intended for systemic delivery. Tablets must be swallowed whole and should not be broken, crushed, divided, or chewed.

Standard Dosing Regimens

Nisaid is generally administered once daily (QD). Dosage is individualized to the lowest effective dose for the shortest duration necessary.

Indication	Standard Daily Dose	Maximum Daily Dose
Adults (OA/RA)	1,200 mg once daily	1,800 mg (or 26 mg/kg)

A lower starting dose of 600 mg once daily may be used for adults with low body weight or milder disease. A one-time loading dose of up to 1,800 mg may be considered when a quick onset of action is desired.

Population-Specific Dosing

Pediatric Dosing (JRA): For children aged 6 to 16 years, the recommended dose is based on body weight, ranging from 600 mg to 1,200 mg once daily. Doses above 1,200 mg daily have not been studied in this population. For patients with severe renal impairment or on dialysis, the initial dose should be 600 mg once daily, and subsequent increases are done cautiously with close monitoring.

Contextual Use Guidelines

While food may reduce the rate of absorption, the extent of Nisaid absorption remains unaffected when taken with meals. Full therapeutic effects may require several days of therapy to be fully achieved.

Recent Clinical Evidence

Research Evidence Overview for Nisaid (Oxaprozin)

Evidence for Use in Osteoarthritis (OA)

Research exploring Oxaprozin for Osteoarthritis (OA) primarily includes short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time in adult patients with OA. Research examined outcomes related to physical discomfort and daily functioning or activity level, with some studies including a comparison to both inactive placebo and other established anti-inflammatory treatments.

Studies focused on assessing how patients reported their experience over defined time intervals. These trials tracked patient-reported outcomes describing perceived discomfort and used functional scales to measure functional limitations. Findings describe measurements of joint pain intensity and assessments of physical ability recorded during the study periods.

Evidence for Use in Rheumatoid Arthritis (RA)

Research exploring Oxaprozin for Rheumatoid Arthritis (RA) included short- to intermediate-term randomized trials that included other common NSAID treatments for comparison. Research examined outcomes related to systemic or functional imbalance, tracking objective measurements of joint tenderness and joint swelling. Studies monitored specific indicators like the duration of morning stiffness and other outcomes capturing phases of heightened symptom activity.

Evidence for Use in Juvenile Rheumatoid Arthritis (JIA)

Research exploring Oxaprozin for Juvenile Rheumatoid Arthritis (JIA) in children 6 years of age and older included specific clinical trials and regulatory documents. The regulatory review also included population pharmacokinetic studies examining drug exposure in children compared to adults. Findings describe that the amount of the drug in the body of the studied pediatric group was observed to be similar to that observed in the adult RA population, which contributed to the evidence base for regulatory review in JIA. This indication is associated with a specific limitation: data for certain groups remain insufficient as the substance has not been studied for use in children younger than 6 years of age.

What the Research Still Does Not Fully Characterize

While a significant body of research exists, there are aspects where the evidence is still developing or limited. The core clinical research for Oxaprozin was applied in studies examining short-term or episodic symptom patterns, meaning the follow-up durations were limited in the most rigorous trials. Long-term effects are not fully established. The core clinical trial evidence currently provides limited data about the results over extended periods. Furthermore, research exploring complex scenarios, such as use in patients with significant existing comorbidities (other health conditions), is not well characterized in the primary efficacy studies. This highlights that research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Nisaid (FAQ)

Q: How quickly can a person expect Nisaid to start working?

According to official product information, initial symptom relief may begin within one week of starting Nisaid. However, it may take up to two weeks or longer to achieve symptom relief in some cases. The full therapeutic effect of the medication may require several weeks of consistent use.

Q: Is there a maximum amount of time Nisaid is typically used for?

Regulatory guidance states that this type of medication should be used at the lowest effective dosage for the shortest duration possible. This principle is emphasized because the risk of serious adverse cardiovascular events may increase with the duration of use. The treatment duration is determined by a healthcare provider based on individual patient goals.

Q: Can Nisaid be used by people who have mild kidney concerns?

Official information indicates that patients with severe renal (kidney) impairment or on dialysis require a significantly reduced starting dose and close monitoring. For those with mild kidney concerns, monitoring of renal function is a stated caution. Use in any patient with kidney concerns is determined by a healthcare provider.

Q: Is Nisaid safe for use in older adults (seniors)?

Official documents state that caution is advised when treating older adults (typically 65 years and older) as they may be more sensitive to the effects of the drug. They are also at a greater documented risk for serious adverse events affecting the stomach, kidneys, and heart.

Q: Is Nisaid likely to interact with common over-the-counter pain relievers?

Other NSAID medicines, such as over-the-counter ibuprofen or naproxen, is cautioned against by official labeling. Combining these medications significantly increases the risk of serious side effects. The use of non-NSAID pain relievers is a matter for discussion with a healthcare provider.

Q: Does Nisaid help with chronic conditions or only acute (short-term) issues?

Nisaid is approved for the relief of signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and juvenile rheumatoid arthritis (JRA). Since these are all chronic inflammatory conditions, the medication is intended for use in managing persistent or long-term issues.

Q: Why is Nisaid sometimes referred to by a different name?

Nisaid is the brand name given by the manufacturer. The medication is also known by its single active ingredient, oxaprozin. Oxaprozin is the generic name commonly used in clinical and regulatory documents, and the drug may be sold under different brand names internationally.

Q: Is it necessary to take Nisaid at the same time every day?

The medication is typically prescribed to be taken once daily. Adherence to the prescribed dosing schedule helps ensure consistent therapeutic levels of the medication are maintained in the body.

Q: How long does the effect of one dose of Nisaid usually last?

The medication is characterized by a long half-life, meaning it remains active in the body for an extended period. The mean elimination half-life for the active ingredient has been reported to be approximately 38 to 55 hours, which is the basis for its once-daily dosing schedule.

Q: Do studies show Nisaid is effective for its intended use?

The medication has received regulatory approval because clinical trials demonstrated outcomes consistent with providing relief from the signs and symptoms of its approved indications. These studies showed effects comparable to those achieved by other standard treatments for osteoarthritis and rheumatoid arthritis.

Q: How does Nisaid affect the liver?

Official warnings note that the use of this medication is associated with a risk of Hepatotoxicity (liver damage). The regulatory safety profile highlights the need for monitoring for symptoms like yellowing of the skin or eyes, excessive tiredness, and flu-like symptoms. Official labeling notes that discontinuation is advised if abnormal liver tests persist or worsen.

Q: Can Nisaid cause changes to sleep patterns?

The list of potential side effects includes general Nervous System Disorders. Although specific changes to sleep patterns are not typically listed as common effects, drowsiness is a potential symptom. Any changes in alertness or sleep are matters for discussion with a healthcare provider.

Q: Can Nisaid affect fertility?

Regulatory documents include findings from animal studies that showed testicular degeneration in beagle dogs treated with the substance. Potential reproductive concerns are a matter for discussion with a healthcare provider, as this type of information is limited in humans.

Q: Are there any specific food items or supplements that should not be taken while using Nisaid?

Official guidance states that a full disclosure of all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products is necessary. Alcohol is specifically noted in regulatory documents to increase the risk of gastrointestinal bleeding when used concomitantly.

Q: What happens if a person misses a dose of Nisaid?

Official patient information provides specific instructions regarding missed doses, which must be followed precisely. These instructions detail when to take a missed dose and when to skip it in order to maintain the appropriate dosing schedule.

Q: Is it normal to feel slightly dizzy when first starting Nisaid?

Dizziness is listed as a potential side effect of this medication in official safety documents. Any symptoms experienced are matters for discussion with a healthcare provider.

Q: Does Nisaid have an official warning about driving or operating machinery?

Official patient information states that activities requiring alertness, such as driving or operating machinery, should be avoided until the individual is certain they can perform them safely. This is due to the potential for side effects like severe dizziness.

Q: Where can I find the official prescribing information (like the FDA label) for Nisaid?

The official prescribing information, often referred to as the drug label, can be found on regulatory websites. Key sources include the FDA (Food and Drug Administration) or the DailyMed (NIH) website by searching for the active ingredient, oxaprozin.

Q: Can Nisaid change the results of certain blood tests?

The regulatory safety profile includes warnings about potential Hematologic Toxicity (effects on blood components). This is why blood values such as hemoglobin or hematocrit are sometimes monitored during treatment.

Q: What happens if someone accidentally takes too much Nisaid?

Symptoms of an overdose may include drowsiness, vomiting, stomach pain, or blood in the stool. Official guidance states that if an overdose is suspected, emergency medical services or a Poison Help line should be contacted immediately.

Q: Does Nisaid contain aspirin or related compounds?

Nisaid's active ingredient, oxaprozin, is classified in the same drug class (Non-Steroidal Anti-Inflammatory Drug - NSAID) as aspirin, but it is a different chemical compound. It is specifically contraindicated for patients who have had an allergic reaction (like asthma or hives) to aspirin.

Q: Can Nisaid cause weight gain or weight loss?

Official safety information notes that unexplained weight gain or swelling in the feet, ankles, or legs are symptoms that require the attention of a healthcare provider. This can be a sign of fluid retention or heart problems. Weight loss is not generally listed as a common effect of the medication.

Q: Is it safe to stop taking Nisaid suddenly?

The medication is used for symptom relief, and official labeling does not contain specific warnings about withdrawal symptoms upon cessation. However, the dose and duration of use are determined by a healthcare provider based on the individual patient's treatment goals.

Q: Are there specific symptoms that signal a serious side effect from Nisaid?

Official safety information describes several serious symptoms that warrant immediate attention from a healthcare provider. These include signs of heart problems (chest pain, slurred speech, sudden weakness), signs of internal bleeding (bloody, black, or tarry stools; vomiting material like coffee grounds), or signs of liver problems (yellowing of the skin or eyes, severe fatigue).

How should Nisaid be stored and disposed of?

How to Store and Dispose of Nisaid (Oxaprozin)

Official regulatory documents define specific requirements for storing and disposing of Nisaid tablets to ensure stability and public safety.

Storage Requirements

Nisaid must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and the cap must be tightly closed to protect the tablets from moisture and excessive heat. A mandatory requirement is to keep this medication out of the reach of children at all times.

Disposal Instructions

Unused or expired Nisaid should be disposed of through a drug take-back program when available. If a take-back program is not accessible, the drug must be mixed with an undesirable substance (e.g., dirt) and placed in a sealed bag before being thrown into the household trash. The tablets must not be flushed down the toilet or poured down a drain.

Nisaid